Sign in
Taking peopleNo phase

Unveiling Maternal-fetal BRAin-body Interactions in Pregnant WOmen Affected by Depression

Key facts

Who runs it
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Where
Germany, Italy, and Spain3 sites in 3 countriesChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
720 people, planned
Started
29 Apr 2026
Expected to end
Jun 2028
Type of study
Interventional, 2 groups
Treatments tested
  • Multimodal MRI and EEG-ECG/PPG recordings
  • Biological sampling
  • Clinical and neurodevelopmental assessments
Record updated
12 November 2026

Who can take part

Age
Up to 45 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 28 criteriaShow less

Who can take part

  • Pregnant women with major depressive disorder (Group 1):
  • Signed informed consent and ability to understand and provide it
  • Age between 18 and 45 years
  • IQ > 70 (4 subtests of WAIS-IV: Vocabulary, Similarities, Block Design, Matrix Reasoning)
  • Diagnosis of major depressive disorder according to the SCID-5-CV at screening (within 20 gestational weeks); Pregnant women without depression (Group 2):
  • Signed informed consent and ability to understand and provide it
  • Age between 18 and 45 years
  • IQ > 70 (4 subtests of WAIS-IV: Vocabulary, Similarities, Block Design, Matrix Reasoning)
  • No current or past psychiatric disorders (SCID-5-CV)
  • No family history of psychiatric disorders (SCID-5-CV and FIGS); Placental tissue sampling (Milan only, Groups 1 and 2):
  • Elective cesarean delivery
  • Absence of labor; Newborns:
  • Informed consent signed by both parents
  • Full-term birth (gestational age at birth of 37 weeks or more)

Who cannot take part

  • Use of systemic corticosteroids
  • Severe prior obstetric conditions
  • History of head trauma with loss of consciousness
  • Neurological or degenerative disorders
  • Comorbid psychiatric disorders
  • History of perinatal alcohol or drug abuse
  • Infectious or autoimmune diseases
  • Congenital, genetic or neurological disorders affecting the mother or the fetus
  • Congenital, genetic or neurological disorder of the newborn
  • Pregnant women (Groups 1 and 2):
  • Twin pregnancy
  • Pregnancy resulting from assisted reproductive technology with egg donation
  • Body mass index (BMI) > 30
  • Absolute or relative contraindications to MRI; Newborns:

This trial has no sites in United States.

It has sites in 3 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this study is to learn how depression during pregnancy is linked to changes in the brain and body of the mother and to the development of the baby, in pregnant women with major depressive disorder (MDD) and pregnant women without depression.

Read full original descriptionShow less

The main questions it aims to answer are:

* How common is major depressive disorder during pregnancy in a European multi-site cohort? * Do pregnant women with MDD show differences in hippocampal volume compared with pregnant women without depression? * Do maternal blood, placenta, cord blood, brain imaging and heart activity measures, and the brain and development of the babies, differ between the two groups?

Pregnant women will be screened within the 20th week of pregnancy and assigned to the MDD group or to the control group based on a structured clinical interview. They will not receive any study drug: women with depression will receive the usual care recommended by clinical guidelines.

Participants will:

* Have clinical, psychiatric and psychological assessments (interviews and questionnaires) at screening, at 22, 26 and 32 weeks of pregnancy, at birth, and at 1 and 6 months after birth * Have a brain MRI with simultaneous EEG-ECG or photoplethysmography (PPG) at about 22 weeks of pregnancy * Have a fetal MRI by 22 weeks and fetal ultrasound scans at 22, 26 and 32 weeks * Give blood samples at 22, 26 and 32 weeks of pregnancy, and a cord blood sample at birth (placenta samples in a subgroup at the Milan center only)

Their newborns will have a neurological and visual examination, a brain MRI and an EEG-ECG or PPG recording after birth, and a developmental assessment (Bayley Scales) at 6 months.

The 2 groups in the trial

  • Pregnant Women With Major Depressive Disorder (Group 1)Other group

    Pregnant women aged 18-45 years diagnosed with major depressive disorder (SCID-5-CV) at screening (within 20 gestational weeks), followed until 6 months postpartum, and their newborns. Participants receive standard clinical care for depression, which may include SSRI antidepressants; no study drug is administered.

    Treatment: Multimodal MRI and EEG-ECG/PPG recordings, Biological sampling, and Clinical and neurodevelopmental assessments

  • Pregnant Women Without Depression (Group 2)Other group

    Pregnant women aged 18-45 years without current or past psychiatric disorders and without family history of psychiatric disorders (SCID-5-CV and FIGS), followed until 6 months postpartum, and their newborns.

    Treatment: Multimodal MRI and EEG-ECG/PPG recordings, Biological sampling, and Clinical and neurodevelopmental assessments

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Record updated
12 November 2026
Unveiling Maternal-fetal BRAin-body Interactions in Pregnant WOmen Affected by Depression (NCT07932093) – Frontlight Research